Incentives Plus Bupropion for Smoking in Schizophrenics

精神分裂症患者吸烟的激励加安非他酮

• 批准号: 6920591
• 负责人: JENNIFER W. TIDEY
• 金额: $ 0.63万
• 依托单位: BROWN UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-09-30 至 2007-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6920591
• 关键词: behavior modification; behavioral /social science research tag; bupropion; clinical research; cognition; gender difference; human subject; motivation; reinforcer; schizophrenia; smoking cessation; tobacco abuse

DESCRIPTION (provided by applicant): There is a high prevalence of cigarette smoking among people with schizophrenia, but few smoking treatments have been developed for these patients. Laboratory and clinical studies have begun to delineate environmental and biological factors that affect smoking in schizophrenics. Recent laboratory feasibility studies have shown promising results with contingent monetary reinforcement for smoking reductions. Similarly, several smoking treatment studies in schizophrenics have shown promising results with bupropion- SR. Our long-term goal is to develop an effective, feasible, research-based smoking cessation program for smokers with schizophrenia. In this laboratory-based feasibility study, we will evaluate 128 male and female smokers with schizophrenia who are interested in quitting smoking in the future, using a 2 x 2 between groups factorial design. The primary aims are: (1) to evaluate the efficacy of a novel contingency management procedure for shaping smoking abstinence by reinforcing salivary cotinine reductions, compared to non-contingent reinforcement; (2) to evaluate the efficacy of 300 mg/day bupropion-SR, compared to placebo; (3) to evaluate the efficacy of combining contingent reinforcement for smoking reductions with bupropion, versus either intervention alone. Secondary aims are (1) to evaluate whether gender or individual differences in nicotine dependence and motivation moderate responsivity to each intervention; (2) to evaluate whether abstinence is related to changes in psychiatric symptoms, extrapyramidal symptoms or cognitive functioning. This study will provide significant information regarding the efficacy and feasibility of using a combination of contingency management and smoking pharmacotherapy to treat smoking in schizophrenics.

描述（由申请人提供）：精神分裂症患者中吸烟的患病率很高，但针对这些患者开发的吸烟治疗方法很少。实验室和临床研究已经开始描绘影响精神分裂症患者吸烟的环境和生物因素。最近的实验室可行性研究表明，随着对吸烟减少的应急货币强化，结果很有希望。同样，精神分裂症患者的几项吸烟治疗研究显示，安非他酮SR的结果很有希望。我们的长期目标是为精神分裂症吸烟者制定一个有效的、可行的、以研究为基础的戒烟计划。在这项基于实验室的可行性研究中，我们将评估128名有兴趣在未来戒烟的精神分裂症男性和女性吸烟者，采用2 × 2组间析因设计。主要目标是：（1）评价通过加强唾液可替宁减少而形成戒烟的新型应急管理程序与非应急强化相比的有效性;（2）评价300 mg/天安非他酮SR与安慰剂相比的有效性;（3）评价将应急强化与安非他酮联合用于减少吸烟与单独干预相比的有效性。次要目的是（1）评价尼古丁依赖和动机的性别或个体差异是否调节对每种干预的反应;（2）评价戒烟是否与精神症状、锥体外系症状或认知功能的变化相关。这项研究将提供重要的信息，关于使用应急管理和吸烟药物治疗相结合，以治疗精神分裂症吸烟的有效性和可行性。